Intelligence · Clinical Development
Pipeline search results
Programs matching “rheumatoid-arthritis” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 82 pipeline programs matching "rheumatoid-arthritis" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Allogeneic NK Cells
Artiva Biotherapeutics
Refractory Rheumatoid Arthritis (RA)
1 trial -
BGB-45035
BEONE MEDICINES AUS PTY LTD
Rheumatoid Arthritis
1 trial -
BMS-945429 Placebo
CSL Behring GmbH
Rheumatoid Arthritis
1 trial -
CF101
Can-Fite BioPharma
Rheumatoid Arthritis
3 trials -
Fostamatinib
AstraZeneca
Rheumatoid Arthritis
1 trial -
Fostamatinib disodium (R935788)
RIGEL PHARMACEUTICALS INC
Rheumatoid Arthritis
2 trials -
GLPG0259 oral capsule
Lakefront Biotherapeutics NV
Rheumatoid Arthritis
1 trial -
GLPG0634
Lakefront Biotherapeutics NV
Rheumatoid Arthritis
4 trials -
GLPG3970
Lakefront Biotherapeutics NV
Rheumatoid Arthritis
1 trial -
ISIS 104838
IONIS PHARMACEUTICALS INC
Rheumatoid Arthritis
1 trial -
ISIS CRP Rx or Placebo
IONIS PHARMACEUTICALS INC
Rheumatoid Arthritis
1 trial -
KYV101
Kyverna Therapeutics
Rheumatoid Arthritis
1 trial -
LX3305 low dose
LEXICON PHARMACEUTICALS, INC.
Rheumatoid Arthritis
1 trial -
LY3871801
RIGEL PHARMACEUTICALS INC
Rheumatoid Arthritis
1 trial -
Namilumab
Takeda
Rheumatoid Arthritis
2 trials -
Natrunix
XBiotech Germany GmbH
Rheumatoid Arthritis
1 trial -
Natrunix 400 mg
XBiotech Germany GmbH
Rheumatoid Arthritis
1 trial -
Natrunix with MTX placebo (+folate)
XBiotech Germany GmbH
Rheumatoid Arthritis
1 trial -
Ocrelizumab
Hoffmann-La Roche
Rheumatoid Arthritis
1 trial -
P38 Inhibitor (4) 150mg
Hoffmann-La Roche
Rheumatoid Arthritis
1 trial -
PF-06650833
Pfizer
Rheumatoid Arthritis
1 trial -
Placebo
Vertex Pharmaceuticals (Australia) Pty.
Rheumatoid Arthritis
1 trial -
R788
RIGEL PHARMACEUTICALS INC
Rheumatoid Arthritis
1 trial -
SPY002-072
Spyre Therapeutics
Rheumatoid Arthritis
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.